The first month at 2.5 mg is an initiation dose, and meaningful weight loss typically begins during the second month at 5 mg
Non-Melanoma Skin Cancer NON-MELANOMA SKIN CANCER IS THE MOST COMMON FORM OF CANCER IN THE UK, 1 IN 3 MEN AND 1 IN 4 WOMEN WILL DEVELOP NON-MELANOMA SKIN CANCER IN THEIR LIFETIME
Weight loss may be slower, but if the lower dose is sustainable and still producing results, that is a reasonable approach
Their use constitutes off-label administration, and the current clinical evidence for their efficacy in this context is limited
Reisch N, Taylor AE, Nogueira EF, Asby DJ, Dhir V, Berry A, Krone N, Auchus RJ, Shackleton CHL, Hanley NA, Arlt W
Sun Z, Wu J, Bi Q, Wang W